<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several aspects of prognosis of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> were reviewed with special attention to <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) </plain></SENT>
<SENT sid="1" pm="."><plain>The median survivals were 14 months in <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 16 months in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 42 months in RA, and 58 months in RA with ring sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Cumulative <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free rates at 5 years were 31% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 80% in RA, and 92% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The proportion of cases having very low hazards for leukemic transformation or for nonleukemic <z:hpo ids='HP_0011420'>death</z:hpo> was 92% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 73% (RA), and 26% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) for leukemic transformation and 23% (RA) and 29% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) for nonleukemic <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> cases had hazard for nonleukemic <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In RA, the annual mortality rate was about 5 to 11 times higher than that of age-and sex- matched general population up to 6 years </plain></SENT>
<SENT sid="6" pm="."><plain>After which no failure was found in RA cases with survival rate of 33% up to 14 years </plain></SENT>
<SENT sid="7" pm="."><plain>The relative importance of hazard from leukemic transformation to nonleukemic <z:hpo ids='HP_0011420'>death</z:hpo> in RA was about one half at presentation, but this declined to less than 10% after 10 years </plain></SENT>
</text></document>